Primecap Management Co. CA Raises Stock Holdings in Danaher Corporation $DHR

Primecap Management Co. CA increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 17.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,449,920 shares of the conglomerate’s stock after buying an additional 210,600 shares during the period. Primecap Management Co. CA’s holdings in Danaher were worth $287,461,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Intech Investment Management LLC grew its holdings in shares of Danaher by 33.8% in the third quarter. Intech Investment Management LLC now owns 22,615 shares of the conglomerate’s stock valued at $4,484,000 after purchasing an additional 5,719 shares during the period. US Bancorp DE lifted its holdings in Danaher by 1.5% during the 3rd quarter. US Bancorp DE now owns 578,898 shares of the conglomerate’s stock worth $114,773,000 after buying an additional 8,557 shares in the last quarter. RWA Wealth Partners LLC boosted its holdings in Danaher by 14.1% in the third quarter. RWA Wealth Partners LLC now owns 92,301 shares of the conglomerate’s stock valued at $18,300,000 after purchasing an additional 11,410 shares during the period. Cary Street Partners Financial LLC grew its position in shares of Danaher by 12.9% during the third quarter. Cary Street Partners Financial LLC now owns 6,773 shares of the conglomerate’s stock worth $1,343,000 after buying an additional 773 shares in the last quarter. Finally, Bradley Foster & Sargent Inc. CT lifted its position in shares of Danaher by 0.8% during the 3rd quarter. Bradley Foster & Sargent Inc. CT now owns 527,158 shares of the conglomerate’s stock worth $104,514,000 after purchasing an additional 4,142 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of a number of research reports. Evercore reissued an “outperform” rating and issued a $254.00 price target on shares of Danaher in a research report on Wednesday, January 28th. Argus set a $265.00 price target on Danaher in a report on Wednesday, January 14th. HSBC boosted their price objective on shares of Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, December 1st. Wells Fargo & Company raised their price objective on shares of Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Finally, TD Cowen restated a “buy” rating on shares of Danaher in a research report on Wednesday, January 7th. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $253.86.

Insider Activity

In other news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the sale, the executive vice president owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.10% of the stock is currently owned by insiders.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Board approved a quarterly cash dividend of $0.40 per share (25% raise from $0.32), payable April 24 to holders of record March 27 — signals capital‑return focus and board confidence, though yield remains modest (~0.8%). Danaher Announces Quarterly Dividend
• Positive Sentiment: Danaher’s announced all‑cash acquisition of Masimo (~$9.9B at $180/share) is framed as a strong strategic fit that expands diagnostics/life‑sciences capabilities; the deal can boost growth and product breadth if integration goes smoothly. All-Cash Masimo Deal Offers Strong Strategic Fit For Danaher Corporation (DHR)
• Positive Sentiment: Company commentary and coverage point to improvement in Danaher’s bioprocessing business — an area with higher margins and growth potential that could lift organic revenue and investor sentiment. Danaher (DHR) is Gaining from Improvement in Its Bioprocessing Business
• Neutral Sentiment: CEO Rainer M. Blair will present at the TD Cowen Healthcare Conference (webcast March 3) — a near‑term event where management could provide updated guidance or M&A/integration details; useful but informational. Danaher to Present at TD Cowen Health Care Conference
• Neutral Sentiment: Relative performance notes: some research flags near‑term weakness versus peers, but analysts retain conviction in a recovery — this frames the stock as having short‑term volatility risk but longer‑term upside tied to execution. How Is Danaher Corporation’s Stock Performance Compared to other Health Care Stocks?

Danaher Stock Performance

Shares of DHR stock opened at $209.70 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87. The firm has a market capitalization of $148.12 billion, a price-to-earnings ratio of 41.61, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. The company has a 50 day moving average price of $225.92 and a 200 day moving average price of $216.13. Danaher Corporation has a one year low of $171.00 and a one year high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 27th. The conglomerate reported $2.23 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The firm had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.79 billion. Danaher had a net margin of 14.71% and a return on equity of 10.81%. Danaher’s revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.14 earnings per share. Sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. Danaher’s dividend payout ratio is presently 25.40%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.